Kexing Pharmaceutical

Kexing Biopharm is a prominent Chinese biopharmaceutical company focused on the research, development, production, and commercialization of recombinant protein therapeutics and microecological preparations. The company's core portfolio includes market-leading products such as EPOSINO (erythropoietin), WHITE-C (filgrastim), and SINOGEN (interferon α1b), which address significant needs in oncology, nephrology, and infectious diseases. Beyond its established protein drugs, Kexing is aggressively expanding into the biosimilar market through strategic partnerships and internal R&D, targeting global markets with monoclonal antibodies like adalimumab and rituximab. The company operates high-standard manufacturing facilities in Shenzhen and Jinan and maintains a robust international distribution network covering over 30 countries. Kexing Biopharm is listed on the Shanghai Stock Exchange STAR Market and continues to pivot toward a globalized innovation-driven business model.